Alison Abraham
Concepts (304)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 51 | 2024 | 2720 | 4.420 |
Why?
| Cognitive Dysfunction | 6 | 2023 | 346 | 2.600 |
Why?
| Sexual and Gender Minorities | 6 | 2021 | 194 | 2.280 |
Why?
| Retinal Vessels | 4 | 2022 | 65 | 2.220 |
Why?
| Renal Insufficiency, Chronic | 14 | 2024 | 566 | 1.730 |
Why?
| Dry Eye Syndromes | 5 | 2024 | 53 | 1.560 |
Why?
| Glomerular Filtration Rate | 19 | 2024 | 711 | 1.420 |
Why?
| Tomography, Optical Coherence | 3 | 2023 | 187 | 1.400 |
Why?
| Homosexuality, Male | 8 | 2021 | 175 | 1.380 |
Why?
| Viral Load | 10 | 2021 | 448 | 1.260 |
Why?
| Cognition Disorders | 2 | 2023 | 505 | 1.200 |
Why?
| Antiretroviral Therapy, Highly Active | 9 | 2018 | 267 | 1.180 |
Why?
| Vision Disorders | 4 | 2023 | 135 | 1.180 |
Why?
| Hearing Loss | 4 | 2023 | 210 | 1.060 |
Why?
| Depression | 4 | 2020 | 1307 | 1.040 |
Why?
| Bias | 4 | 2022 | 196 | 0.950 |
Why?
| Vitamin D Deficiency | 2 | 2017 | 176 | 0.950 |
Why?
| Anti-Retroviral Agents | 5 | 2018 | 231 | 0.920 |
Why?
| AIDS-Associated Nephropathy | 4 | 2017 | 7 | 0.910 |
Why?
| Atherosclerosis | 4 | 2022 | 402 | 0.890 |
Why?
| Anti-HIV Agents | 7 | 2018 | 754 | 0.890 |
Why?
| Masks | 1 | 2023 | 59 | 0.820 |
Why?
| Hypertension | 6 | 2023 | 1242 | 0.810 |
Why?
| Cognitive Aging | 1 | 2023 | 16 | 0.810 |
Why?
| Cohort Studies | 26 | 2023 | 5420 | 0.790 |
Why?
| Fluorescein Angiography | 2 | 2022 | 143 | 0.780 |
Why?
| CD4 Lymphocyte Count | 11 | 2021 | 266 | 0.780 |
Why?
| Diabetes Mellitus | 5 | 2022 | 1001 | 0.780 |
Why?
| Eye | 1 | 2023 | 104 | 0.770 |
Why?
| Male | 59 | 2023 | 63682 | 0.730 |
Why?
| Cross-Sectional Studies | 19 | 2023 | 5066 | 0.710 |
Why?
| Visually Impaired Persons | 1 | 2020 | 3 | 0.700 |
Why?
| Aged | 26 | 2023 | 22104 | 0.680 |
Why?
| Adult Survivors of Child Adverse Events | 1 | 2020 | 12 | 0.680 |
Why?
| Glaucoma | 1 | 2023 | 219 | 0.660 |
Why?
| Humans | 87 | 2024 | 129652 | 0.650 |
Why?
| Middle Aged | 46 | 2021 | 31155 | 0.630 |
Why?
| Cognition | 4 | 2023 | 1123 | 0.620 |
Why?
| Viremia | 2 | 2018 | 131 | 0.600 |
Why?
| Crime Victims | 1 | 2020 | 112 | 0.590 |
Why?
| Body Size | 1 | 2018 | 102 | 0.570 |
Why?
| HIV | 6 | 2020 | 226 | 0.570 |
Why?
| Vitamin D | 2 | 2018 | 384 | 0.560 |
Why?
| Kidney Diseases | 4 | 2014 | 384 | 0.540 |
Why?
| Kidney | 12 | 2024 | 1385 | 0.540 |
Why?
| Survivors | 1 | 2020 | 464 | 0.530 |
Why?
| Hepatitis C | 4 | 2023 | 238 | 0.520 |
Why?
| Immunologic Factors | 1 | 2018 | 231 | 0.510 |
Why?
| Psychiatric Status Rating Scales | 1 | 2018 | 529 | 0.490 |
Why?
| Dementia | 1 | 2019 | 227 | 0.490 |
Why?
| Kidney Failure, Chronic | 3 | 2017 | 547 | 0.480 |
Why?
| Risk Factors | 25 | 2024 | 9765 | 0.480 |
Why?
| Prospective Studies | 19 | 2022 | 7133 | 0.470 |
Why?
| Body Composition | 2 | 2018 | 649 | 0.470 |
Why?
| Microbiota | 1 | 2023 | 730 | 0.470 |
Why?
| Depressive Disorder | 1 | 2018 | 366 | 0.460 |
Why?
| Aging | 3 | 2023 | 1776 | 0.460 |
Why?
| Female | 48 | 2024 | 68777 | 0.450 |
Why?
| Executive Function | 2 | 2023 | 431 | 0.430 |
Why?
| Attention | 1 | 2017 | 438 | 0.430 |
Why?
| Biomarkers | 14 | 2024 | 3973 | 0.410 |
Why?
| Adult | 44 | 2023 | 35577 | 0.400 |
Why?
| Substance-Related Disorders | 1 | 2021 | 1022 | 0.390 |
Why?
| Stress, Psychological | 1 | 2020 | 1066 | 0.370 |
Why?
| Prevalence | 7 | 2022 | 2564 | 0.370 |
Why?
| Anemia | 1 | 2012 | 160 | 0.350 |
Why?
| Comorbidity | 4 | 2021 | 1547 | 0.340 |
Why?
| Longitudinal Studies | 6 | 2022 | 2717 | 0.330 |
Why?
| United States | 18 | 2024 | 13903 | 0.330 |
Why?
| Independent Living | 2 | 2022 | 98 | 0.320 |
Why?
| Creatinine | 9 | 2023 | 491 | 0.310 |
Why?
| Metabolomics | 3 | 2023 | 652 | 0.310 |
Why?
| Aged, 80 and over | 8 | 2023 | 7086 | 0.300 |
Why?
| Hospitals | 2 | 2023 | 637 | 0.300 |
Why?
| Neuropsychological Tests | 4 | 2022 | 1015 | 0.300 |
Why?
| Bone Density | 2 | 2022 | 471 | 0.290 |
Why?
| Incidence | 9 | 2022 | 2644 | 0.260 |
Why?
| Sensitivity and Specificity | 3 | 2018 | 1838 | 0.240 |
Why?
| Iohexol | 2 | 2015 | 19 | 0.230 |
Why?
| HIV-1 | 5 | 2017 | 836 | 0.230 |
Why?
| Renal Insufficiency | 2 | 2017 | 149 | 0.230 |
Why?
| Kidney Function Tests | 4 | 2017 | 152 | 0.220 |
Why?
| Tears | 1 | 2023 | 28 | 0.220 |
Why?
| Genes, rRNA | 1 | 2023 | 41 | 0.210 |
Why?
| Plaque, Atherosclerotic | 1 | 2023 | 55 | 0.210 |
Why?
| Cornea | 1 | 2023 | 128 | 0.200 |
Why?
| Optic Disk | 1 | 2023 | 40 | 0.200 |
Why?
| Ophthalmic Solutions | 1 | 2023 | 74 | 0.200 |
Why?
| RNA, Viral | 4 | 2020 | 619 | 0.200 |
Why?
| Dietary Proteins | 1 | 2023 | 129 | 0.200 |
Why?
| Sex Hormone-Binding Globulin | 1 | 2022 | 53 | 0.200 |
Why?
| Metabolome | 2 | 2023 | 338 | 0.190 |
Why?
| Drug Users | 1 | 2022 | 41 | 0.190 |
Why?
| Epidemiologic Studies | 1 | 2022 | 65 | 0.190 |
Why?
| Cancellous Bone | 1 | 2021 | 21 | 0.190 |
Why?
| Hypotension | 1 | 2023 | 116 | 0.190 |
Why?
| Pseudouridine | 1 | 2021 | 4 | 0.190 |
Why?
| Uridine | 1 | 2021 | 29 | 0.190 |
Why?
| Alcohol Drinking | 2 | 2019 | 764 | 0.180 |
Why?
| DNA, Bacterial | 1 | 2023 | 324 | 0.180 |
Why?
| Femur Neck | 1 | 2021 | 60 | 0.180 |
Why?
| Alpha-Globulins | 3 | 2017 | 20 | 0.180 |
Why?
| Odds Ratio | 4 | 2018 | 1023 | 0.180 |
Why?
| Ascaris | 1 | 2020 | 2 | 0.180 |
Why?
| Age Factors | 5 | 2020 | 3144 | 0.170 |
Why?
| North America | 3 | 2017 | 291 | 0.170 |
Why?
| RNA, Ribosomal, 16S | 1 | 2023 | 525 | 0.170 |
Why?
| Social Determinants of Health | 1 | 2024 | 221 | 0.170 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2021 | 2441 | 0.170 |
Why?
| Sickness Impact Profile | 1 | 2020 | 55 | 0.170 |
Why?
| Visual Acuity | 1 | 2022 | 322 | 0.170 |
Why?
| Survival Analysis | 3 | 2018 | 1274 | 0.170 |
Why?
| Sex Factors | 4 | 2018 | 1968 | 0.160 |
Why?
| Adenosine | 1 | 2021 | 227 | 0.160 |
Why?
| Kidney Transplantation | 2 | 2017 | 672 | 0.160 |
Why?
| Malnutrition | 1 | 2020 | 79 | 0.160 |
Why?
| Disease Progression | 7 | 2023 | 2635 | 0.160 |
Why?
| Serum Albumin | 2 | 2024 | 149 | 0.160 |
Why?
| Inpatients | 1 | 2023 | 467 | 0.160 |
Why?
| Multicenter Studies as Topic | 1 | 2020 | 286 | 0.160 |
Why?
| Retinal Diseases | 1 | 2020 | 88 | 0.160 |
Why?
| Follow-Up Studies | 5 | 2021 | 4897 | 0.160 |
Why?
| Interleukin-18 | 5 | 2024 | 237 | 0.150 |
Why?
| Prognosis | 5 | 2018 | 3794 | 0.150 |
Why?
| Carotid Intima-Media Thickness | 1 | 2019 | 90 | 0.150 |
Why?
| Prediabetic State | 1 | 2021 | 246 | 0.150 |
Why?
| Substance Abuse, Intravenous | 2 | 2017 | 108 | 0.150 |
Why?
| Epidemiologic Research Design | 1 | 2018 | 28 | 0.150 |
Why?
| Cerebrovascular Disorders | 1 | 2019 | 90 | 0.150 |
Why?
| Glucocorticoids | 1 | 2022 | 575 | 0.150 |
Why?
| Bisexuality | 1 | 2018 | 30 | 0.140 |
Why?
| Hand Strength | 2 | 2022 | 113 | 0.140 |
Why?
| Hyperglycemia | 1 | 2021 | 328 | 0.140 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 2016 | 123 | 0.140 |
Why?
| Case-Control Studies | 6 | 2023 | 3381 | 0.140 |
Why?
| Retrospective Studies | 6 | 2023 | 14518 | 0.140 |
Why?
| Acetylglucosaminidase | 2 | 2016 | 5 | 0.140 |
Why?
| Cystatin C | 2 | 2016 | 65 | 0.140 |
Why?
| Sustained Virologic Response | 1 | 2017 | 37 | 0.140 |
Why?
| Coronary Artery Disease | 1 | 2023 | 679 | 0.140 |
Why?
| Hypercholesterolemia | 1 | 2018 | 102 | 0.140 |
Why?
| Dihydroxycholecalciferols | 1 | 2016 | 1 | 0.140 |
Why?
| Tenofovir | 2 | 2016 | 231 | 0.140 |
Why?
| HIV Seropositivity | 2 | 2017 | 119 | 0.130 |
Why?
| Machine Learning | 1 | 2022 | 443 | 0.130 |
Why?
| Geriatric Assessment | 1 | 2018 | 205 | 0.130 |
Why?
| Time Factors | 5 | 2018 | 6556 | 0.130 |
Why?
| Albuminuria | 4 | 2023 | 183 | 0.130 |
Why?
| Data Interpretation, Statistical | 1 | 2018 | 335 | 0.130 |
Why?
| Acute-Phase Proteins | 2 | 2013 | 67 | 0.130 |
Why?
| Lipocalins | 2 | 2013 | 36 | 0.130 |
Why?
| HIV Wasting Syndrome | 1 | 2016 | 4 | 0.130 |
Why?
| Inflammation | 3 | 2018 | 2736 | 0.120 |
Why?
| Hemoglobins | 2 | 2020 | 339 | 0.120 |
Why?
| Alzheimer Disease | 1 | 2021 | 519 | 0.120 |
Why?
| Young Adult | 9 | 2023 | 12427 | 0.120 |
Why?
| Geography | 1 | 2016 | 188 | 0.120 |
Why?
| Sleep Wake Disorders | 1 | 2018 | 252 | 0.120 |
Why?
| Adolescent | 10 | 2023 | 20394 | 0.120 |
Why?
| Continuity of Patient Care | 1 | 2017 | 275 | 0.120 |
Why?
| Patient Care | 1 | 2016 | 109 | 0.120 |
Why?
| Living Donors | 1 | 2017 | 287 | 0.120 |
Why?
| Apolipoproteins | 1 | 2014 | 38 | 0.120 |
Why?
| Reproducibility of Results | 2 | 2023 | 3083 | 0.110 |
Why?
| Immune Tolerance | 1 | 2017 | 355 | 0.110 |
Why?
| Arsenic | 1 | 2015 | 66 | 0.110 |
Why?
| Lipoproteins, HDL | 1 | 2014 | 85 | 0.110 |
Why?
| Canada | 4 | 2017 | 350 | 0.110 |
Why?
| Factor Analysis, Statistical | 1 | 2015 | 284 | 0.110 |
Why?
| HIV Seronegativity | 1 | 2013 | 25 | 0.110 |
Why?
| Kidney Tubules, Proximal | 1 | 2014 | 125 | 0.110 |
Why?
| Models, Theoretical | 1 | 2017 | 547 | 0.110 |
Why?
| Lipodystrophy | 1 | 2013 | 13 | 0.110 |
Why?
| Graft Rejection | 1 | 2017 | 598 | 0.110 |
Why?
| Kidney Glomerulus | 1 | 2014 | 109 | 0.100 |
Why?
| beta 2-Microglobulin | 1 | 2013 | 49 | 0.100 |
Why?
| Reverse Transcriptase Inhibitors | 1 | 2013 | 83 | 0.100 |
Why?
| Proto-Oncogene Proteins | 2 | 2013 | 638 | 0.100 |
Why?
| Organophosphonates | 1 | 2013 | 92 | 0.100 |
Why?
| Pneumocystis carinii | 1 | 2011 | 10 | 0.090 |
Why?
| Antibodies, Fungal | 1 | 2011 | 9 | 0.090 |
Why?
| Patient Compliance | 1 | 2015 | 565 | 0.090 |
Why?
| Cardiovascular Diseases | 1 | 2023 | 2004 | 0.090 |
Why?
| Renal Dialysis | 1 | 2015 | 423 | 0.090 |
Why?
| Pneumonia, Pneumocystis | 1 | 2011 | 35 | 0.090 |
Why?
| Dyslipidemias | 1 | 2013 | 177 | 0.090 |
Why?
| Motor Activity | 1 | 2016 | 676 | 0.090 |
Why?
| Adenine | 1 | 2013 | 256 | 0.090 |
Why?
| Baltimore | 2 | 2021 | 45 | 0.090 |
Why?
| Fungal Proteins | 1 | 2011 | 130 | 0.090 |
Why?
| Healthcare Disparities | 1 | 2017 | 578 | 0.090 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 759 | 0.090 |
Why?
| Risk Assessment | 3 | 2018 | 3240 | 0.090 |
Why?
| Medication Adherence | 1 | 2015 | 558 | 0.080 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 3 | 2016 | 42 | 0.080 |
Why?
| Lipocalin-2 | 3 | 2016 | 75 | 0.080 |
Why?
| Predictive Value of Tests | 4 | 2016 | 1952 | 0.080 |
Why?
| Severity of Illness Index | 2 | 2015 | 2742 | 0.080 |
Why?
| Acute Kidney Injury | 1 | 2016 | 790 | 0.080 |
Why?
| Child | 7 | 2023 | 20883 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2015 | 902 | 0.070 |
Why?
| Homicide | 1 | 2008 | 60 | 0.070 |
Why?
| Surveys and Questionnaires | 1 | 2020 | 5406 | 0.070 |
Why?
| Proportional Hazards Models | 3 | 2017 | 1201 | 0.070 |
Why?
| Hepacivirus | 2 | 2022 | 235 | 0.070 |
Why?
| Brain | 1 | 2019 | 2679 | 0.070 |
Why?
| Membrane Glycoproteins | 3 | 2013 | 474 | 0.060 |
Why?
| Child, Preschool | 4 | 2023 | 10517 | 0.060 |
Why?
| Stroke | 1 | 2013 | 1071 | 0.060 |
Why?
| Primary Health Care | 1 | 2015 | 1680 | 0.060 |
Why?
| Population Surveillance | 2 | 2017 | 439 | 0.050 |
Why?
| Diet, Protein-Restricted | 1 | 2023 | 11 | 0.050 |
Why?
| Treatment Outcome | 1 | 2018 | 10230 | 0.050 |
Why?
| Loteprednol Etabonate | 1 | 2022 | 6 | 0.050 |
Why?
| Intelligence | 1 | 2023 | 130 | 0.050 |
Why?
| Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| Research Design | 2 | 2021 | 1044 | 0.050 |
Why?
| Meibomian Glands | 1 | 2022 | 18 | 0.050 |
Why?
| Receptors, Virus | 2 | 2013 | 83 | 0.050 |
Why?
| Chi-Square Distribution | 2 | 2014 | 516 | 0.050 |
Why?
| Constriction, Pathologic | 1 | 2023 | 228 | 0.050 |
Why?
| Tobramycin | 1 | 2022 | 51 | 0.050 |
Why?
| Neoplasms | 1 | 2017 | 2470 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2023 | 97 | 0.050 |
Why?
| Support Vector Machine | 1 | 2022 | 37 | 0.050 |
Why?
| Sugar Acids | 1 | 2021 | 4 | 0.050 |
Why?
| Citrates | 1 | 2021 | 42 | 0.050 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 43 | 0.050 |
Why?
| Infant | 3 | 2023 | 9024 | 0.050 |
Why?
| Cyclosporine | 1 | 2022 | 263 | 0.050 |
Why?
| Linear Models | 2 | 2014 | 819 | 0.050 |
Why?
| Hearing | 1 | 2022 | 135 | 0.040 |
Why?
| Renal Replacement Therapy | 1 | 2021 | 87 | 0.040 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 170 | 0.040 |
Why?
| Eating | 1 | 2023 | 369 | 0.040 |
Why?
| Memory, Short-Term | 1 | 2023 | 263 | 0.040 |
Why?
| Sulfides | 1 | 2021 | 94 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2022 | 178 | 0.040 |
Why?
| Alanine | 1 | 2021 | 142 | 0.040 |
Why?
| Los Angeles | 1 | 2020 | 63 | 0.040 |
Why?
| Audiometry, Pure-Tone | 1 | 2020 | 28 | 0.040 |
Why?
| Tryptophan | 1 | 2021 | 179 | 0.040 |
Why?
| Cataract | 1 | 2022 | 208 | 0.040 |
Why?
| Microcirculation | 1 | 2020 | 145 | 0.040 |
Why?
| Frailty | 1 | 2022 | 153 | 0.040 |
Why?
| Hydrocortisone | 1 | 2021 | 307 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2022 | 522 | 0.040 |
Why?
| Genotype | 2 | 2014 | 1839 | 0.040 |
Why?
| Bayes Theorem | 1 | 2020 | 375 | 0.040 |
Why?
| Blood Glucose | 2 | 2021 | 2097 | 0.040 |
Why?
| Heterosexuality | 1 | 2018 | 43 | 0.040 |
Why?
| Diabetic Retinopathy | 1 | 2020 | 176 | 0.040 |
Why?
| Multimorbidity | 1 | 2018 | 46 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 1368 | 0.030 |
Why?
| Glucose | 1 | 2022 | 1003 | 0.030 |
Why?
| Logistic Models | 1 | 2022 | 1988 | 0.030 |
Why?
| History, 21st Century | 1 | 2017 | 183 | 0.030 |
Why?
| Nephrectomy | 1 | 2017 | 160 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1214 | 0.030 |
Why?
| Patient Outcome Assessment | 1 | 2017 | 125 | 0.030 |
Why?
| Diet | 1 | 2023 | 1213 | 0.030 |
Why?
| Blood Pressure | 1 | 2023 | 1736 | 0.030 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2016 | 69 | 0.030 |
Why?
| Ultrasonography | 1 | 2019 | 716 | 0.030 |
Why?
| Confidence Intervals | 1 | 2016 | 317 | 0.030 |
Why?
| Demography | 1 | 2016 | 279 | 0.030 |
Why?
| Apolipoprotein L1 | 1 | 2014 | 13 | 0.030 |
Why?
| Graft Survival | 1 | 2017 | 512 | 0.030 |
Why?
| Risk | 1 | 2017 | 854 | 0.030 |
Why?
| Pandemics | 1 | 2022 | 1488 | 0.030 |
Why?
| Proteinuria | 1 | 2014 | 91 | 0.030 |
Why?
| Health | 1 | 2014 | 74 | 0.030 |
Why?
| Nutrition Surveys | 1 | 2015 | 260 | 0.030 |
Why?
| Diagnostic Errors | 1 | 2014 | 162 | 0.030 |
Why?
| Cooperative Behavior | 1 | 2016 | 433 | 0.030 |
Why?
| Sex Characteristics | 1 | 2018 | 737 | 0.030 |
Why?
| Health Policy | 1 | 2016 | 353 | 0.030 |
Why?
| Drug Monitoring | 1 | 2014 | 216 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 1269 | 0.030 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 161 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2013 | 248 | 0.020 |
Why?
| Cholesterol, HDL | 1 | 2013 | 205 | 0.020 |
Why?
| Alleles | 1 | 2014 | 845 | 0.020 |
Why?
| Cholesterol | 1 | 2013 | 412 | 0.020 |
Why?
| Cholesterol, LDL | 1 | 2013 | 358 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2014 | 1502 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2013 | 401 | 0.020 |
Why?
| Serine Endopeptidases | 1 | 2011 | 118 | 0.020 |
Why?
| Triglycerides | 1 | 2013 | 527 | 0.020 |
Why?
| Animals | 2 | 2023 | 35361 | 0.020 |
Why?
| Immunoglobulin M | 1 | 2011 | 275 | 0.020 |
Why?
| Interleukin-6 | 1 | 2013 | 720 | 0.020 |
Why?
| Adipose Tissue | 1 | 2013 | 592 | 0.020 |
Why?
| Social Problems | 1 | 2008 | 12 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 833 | 0.020 |
Why?
| Tanzania | 1 | 2008 | 44 | 0.020 |
Why?
| Age Distribution | 1 | 2008 | 372 | 0.020 |
Why?
| Sex Distribution | 1 | 2008 | 359 | 0.020 |
Why?
| Chronic Disease | 1 | 2013 | 1720 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2011 | 847 | 0.020 |
Why?
| Cause of Death | 1 | 2008 | 393 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2014 | 2282 | 0.020 |
Why?
| Insulin Resistance | 1 | 2013 | 1165 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2013 | 2535 | 0.010 |
Why?
|
|
Abraham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|